ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Pfizer's Xeljanz scores EU approval for active psoriatic arthritis
July 06, 2018With the decision, Xeljanz becomes the first and only oral Janus kinase inhibitor to be approved in the European Union (EU) for the treatment of adults with active PsA. -
Pfizer eyes gastro use for Xeljanz after thumbs-up from FDA advisers
March 12, 2018Pfizer has been steadily building a franchise around its inflammatory diseases pill, Xeljanz (tofacitinib) over the last few years, and it could add another use after US experts recommended a licence in ulcerative colitis. -
Pfizer’s Xeljanz wins US nod for psoriatic arthritis
December 19, 2017Pfizer Xeljanz and Xeljanz XR have received US marketing clearance for the treatment of adults with active psoriatic arthritis (PsA) who have failed to respond or are intolerant to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
Pharma Sources Insight January 2025
